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Abstract
Background: Emotional disorders (depression and anxiety disorders) are highly prevalent mental health problems.
Although evidence showing the effectiveness of disorder-specific treatments exists, high comorbidity rates among
emotional disorders limit the utility of these protocols. This has led some researchers to focus their interest on
transdiagnostic interventions, a treatment perspective that might be more widely effective across these disorders.
Also, the current way of delivering treatments makes it difficult provide assistance to all of the population in need.
The use of the Internet in the delivery of evidence-based treatments may help to disseminate treatments among
the population. In this study, we aim to test the effectiveness of EmotionRegulation, a new transdiagnostic
Internet-based protocol for unipolar mood disorders, five anxiety disorders (panic disorder, agoraphobia, social anxiety
disorder, generalized anxiety disorder and anxiety disorder not otherwise specified), and obsessive-compulsive
disorder in comparison to treatment as usual as provided in Spanish public specialized mental health care.
We will also study its potential impact on basic temperament dimensions (neuroticism/behavioral inhibition
and extraversion/behavioral activation). Expectations and opinions of patients about this protocol will also be studied.
Methods/Design: The study is a randomized controlled trial. 200 participants recruited in specialized care will be
allocated to one of two treatment conditions: a) EmotionRegulation or b) treatment as usual. Primary outcome
measures will be the BAI and the BDI-II. Secondary outcomes will include a specific measure of the principal disorder,
and measures of neuroticism/behavioral inhibition and extraversion/behavioral activation. Patients will be assessed at
baseline, post-treatment, and 3- and 12-month follow-ups. Intention to treat and per protocol analyses will be
performed.
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Discussion: Although the effectiveness of face-to-face transdiagnostic protocols has been investigated in
previous studies, the number of published transdiagnostic Internet-based programs is still quite low. To our
knowledge, this is the first randomized controlled trial studying the effectiveness of a transdiagnostic Internet-based
treatment for several emotional disorders in public specialized care. Combining both a transdiagnostic approach with
an Internet-based therapy format may help to decrease the burden of mental disorders, reducing the difficulties
associated with disorder-specific treatments and facilitating access to people in need of treatment. Strengths and
limitations are discussed.
Trial registration: ClinicalTrials.gov NCT02345668. Registered 27 July 2015.
Keywords: Transdiagnostic, Internet, Randomized controlled trial, Emotional disorders, Depression, Anxiety, Computer-
delivered psychotherapy, Neuroticism/behavioral inhibition, Extraversion/behavioral activation
Background
Introduction
Emotional disorders (ED) (anxiety and mood disorders)
are among the most prevalent mental disorders, with a
life prevalence of 29 % and comorbidity rates ranging
between 40 and 80 % [1, 2]. If the person experiencing
the disorder is not adequately treated, the course often
becomes chronic and can significantly affect important
functioning areas such as work and social relationships
[3, 4]. Moreover, the medical care costs and production
losses associated with these mental health problems in
Europe are huge [2]. These data strongly suggest that
efficacious and efficient treatments are needed to ad-
dress this important health problem [5–8]. Nevertheless,
despite these alarming data, evidence exists indicating
that most people with depression and anxiety disorders
(less than 50 %) do not receive treatment. [9]. To reduce
the burden of mental illness, some authors have empha-
sized the need for an approach that goes beyond the
dominant face-to-face treatment approach in order to
provide help to people in need of evidence-based
treatments, and this approach includes the use of the
media, self-help interventions, the use of special set-
tings and information and communication technolo-
gies (ICT) [10].
Efficacious psychological treatments for ED currently
exist, and a number of evidence-based cognitive-
behavioral treatments (CBT) targeting specific disorders
have been developed in the past 20 years [11–17]. How-
ever, disorder-specific treatment protocols have some
problems. First, the high comorbidity rates among ED.
Epidemiological studies have shown that at least 55 % of
people suffering from depression and an anxiety disorder
suffer from another anxiety disorder at the time of
the assessment, and this prevalence rate increases to
76 % when different lifespan diagnoses are taken into
account [18]. Consequently, clinicians often have to
decide on which is the most adequate disorder-
specific protocol in these cases, and because these
treatments focus on disorder-specific symptomatology,
other comorbid diagnoses do not receive sufficient at-
tention [19]. Second, disorder-specific protocols fre-
quently do not target subthreshold symptoms that did
not meet diagnostic thresholds for one disorder or
another but that may be important to address in the
treatment [20]. Third, the high rate in which “not
otherwise specified” diagnoses of clinical significance
are assigned as current and lifetime conditions for
which there are not specific interventions [18]. Fi-
nally, the fact that each manualized specific-disorder
treatment requires the use of separate handbooks,
workbooks and protocols may be an obstacle in the
dissemination of evidence-treatments due to its costs and
the important amount of training to become adequately
familiar with each of the different treatments [20].
Transdiagnostic approach
In recent years, there has been great interest in treat-
ment strategies (referred to as transdiagnostic treat-
ments) that might be more widely effective across these
diverse mental health disorders. Unlike disorder-specific
treatment protocols, transdiagnostic treatments gener-
ally include treatments aimed at addressing different dis-
orders (for example, different anxiety disorders) with a
single protocol [21]. A growing body of research show-
ing the efficacy of transdiagnostic treatments for anxiety
disorders [22–27], and for comorbid depression and
anxiety disorders [28–30] has emerged in the past years.
Moreover, the efficacy and effectiveness of transdiagnos-
tic treatment protocols for ED have been shown in two
recent meta-analyses [31, 32].
An important line of research within the transdiagnostic
approach is that initiated by D. H. Barlow [20, 33–36].
Barlow’s theory of triple vulnerability emphasizes the
underlying vulnerabilities that are common to emotional
disorders and help to explain the comorbidity among
these diverse conditions [20, 33]. From this theoretical
framework, ED are regarded as minor variations in the
manifestation of a broader syndrome (that is, “general
neurotic syndrome”) such that the development of
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treatments directly targeting this underlying syndrome ra-
ther than symptom-specific variations would result in a
more parsimonious, easier to disseminate treatment
approach [20]. It would also result in a more inclusive
approach, as it lays on the existence of biological and
psychological vulnerabilities that are hypothesized to
be common among anxiety disorders, unipolar mood
disorders, and other disorders such as somatoform and
dissociative disorders [20, 37]. Based on this perspec-
tive, Barlow’s team designed the Unified Protocol (UP)
[37–41], a transdiagnostic treatment protocol that em-
phasizes the role of emotion regulation in understand-
ing and treating ED. Due to difficulties in emotion
regulation, people with ED often react negatively to
their own emotions, and they are more likely to use
maladaptive emotion regulation strategies that, in turn,
increase the frequency and intensity of negative emo-
tions [37]. To enhance adaptive emotion regulation
strategies, the UP focuses on four essential aspects: in-
creasing present-focused emotional awareness, addressing
emotional avoidance, promoting cognitive flexibility, and
facilitating exposure to avoided situations and sensations.
The results obtained using this protocol in a traditional
face-to-face format demonstrate its effectiveness and are
encouraging [30, 38, 42].
The core of all emotion regulation difficulties has been
pointed out to be neuroticism/behavioral inhibition
(N/BI) [34, 43, 44]. Previous research supports the
role of N/BI in accounting for the onset, overlap, and
maintenance of ED [33, 44–46]. Literature has also
highlighted the role of extraversion/behavioral activa-
tion (E/BA) in ED. For instance, structural models
have indicated that low E/BA is associated with uni-
polar depression [47], social anxiety [48] and agora-
phobia [49]. Also, a recent meta-analysis indicated
that most individuals with anxiety and mood disor-
ders show low levels of E/BA [50]. The effect of the
UP on these two temperament dimensions has been
demonstrated recently [51].
Literature about Dialectical Behavior Therapy (DBT)
has also highlighted the role of emotion dysregulation in
psychological disorders [52, 53]. A primary goal in DBT
is training patients in adaptive emotion regulation strat-
egies, as emotion dysregulation is assumed to be a key
factor in the development and maintenance of these
problems [52]. Emotion regulation difficulties have also
been shown to be a transdiagnostic factor across a num-
ber of psychological disorders, including anxiety and de-
pression [54–58]. A treatment protocol derived from
DBT emotion regulation skills training has been tested
in a recent study, suggesting that training patients in
emotion regulation strategies (for example increasing
emotional awareness) may help to reduce anxious and
depressive symptoms among distinct ED [59].
Internet-based treatment protocols
ICT such as the Internet may facilitate access by people
for whom traditional therapy is not available [10].
Internet-based treatments have proven to be a very
promising tool for solving several mental health prob-
lems and enhancing the dissemination of evidence-based
treatments [60–63]. Several advantages regarding the re-
cruitment of patients, assessment, diagnosis and case
management in Internet-based treatment protocols have
been indicated in a recent article [64]. A number of sys-
tematic reviews have shown that Internet-based treat-
ments are efficacious [65–69]. Moreover, meta-analyses
reveal that these protocols produce higher effect sizes
compared to control groups [60, 65, 70] and that they
are as efficacious as face-to-face traditional treatments
[66, 70–72]. In sum, there is extensive evidence showing
the efficacy of these treatments. However, the evidence
available about Internet-based treatments is almost ex-
clusively limited to disorder-specific protocols. Indeed,
very few studies combining both a transdiagnostic
approach and an Internet-based delivery format have
been tested through randomized controlled trials (RCT)
[25, 26, 29, 73]. Moreover, studies analyzing the efficacy
of transdiagnostic Internet-based treatments, address the
treatment of anxiety disorders only [25, 26, 73] or have
used open-trial designs [28, 74]. Among those focused
on anxiety and depression the existing protocols do not
contemplate either the treatment of “not otherwise
specified” diagnoses or obsessive-compulsive disorder
[29], or target a small range of ED [29]. Moreover, to
our knowledge, no RCT have been carried out on the ef-
fectiveness of a transdiagnostic Internet-based protocol
versus treatment as usual (TAU) in public mental spe-
cialized care settings.
Current study
Our research group has developed a traditional trans-
diagnostic treatment that is partly based on the UP
[37]. Taking into account the importance of emotion
regulation in the treatment of ED, it also includes
components of emotion regulation from DBT [52].
Based on the traditional treatment protocol, we devel-
oped EmotionRegulation, an adaptation of this treat-
ment that can be applied online over the Internet.
In this study, we aim to present EmotionRegulation,
and test its effectiveness for the treatment of ED in an
RCT with a sample made up of participants from spe-
cialized care in the Spanish public mental health system,
compared to TAU. The ED targeted in this study will be
major depression disorder (MDD), dysthymic disorder
(DD), panic disorder (PD), agoraphobia (A), social anx-
iety disorder (SAD), generalized anxiety disorder (GAD),
and obsessive-compulsive disorder (OCD). Anxiety dis-
order not otherwise specified (ADNOS) and (unipolar)
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mood disorder not otherwise specified (MDNOS) will
also be targeted. Secondary objectives will include the
following: a) study of the effects of EmotionRegulation
on two dimensions of temperament (that is, N/BI and
E/BA) and b) study of the acceptability (expectations
and opinions) of the online program by patients. In
this article, we present the study design.
Methods/Design
Study design
A two-armed simple-blinded randomized controlled trial
will be conducted. Participants will be randomly allo-
cated to one of two conditions: a) EmotionRegulation
and b) TAU. Randomization will be stratified by pri-
mary diagnosis. Block randomization will be per-
formed within each strata in order to ensure all
primary diagnoses are equally represented across
conditions. The study will be conducted following
the CONSORT statement (Consolidated Standards of
Reporting Trials, http://www.consort-statement.org)
[75, 76] and CONSORT-EHEALTH guidelines [77]. Par-
ticipants will be assessed at pre- and post-treatment, and
at 3- and 12-month follow-ups. The study flowchart is
shown in Fig. 1.
Study population
The clinical trial will be conducted in the Mental Health
Department of the Provincial Consorcio Hospitalario
in Castellon and the University Hospital La Ribera in
Valencia (Spain). Participants will be adult outpatients
from specialized care who attend mental health units to
seek psychological and/or psychiatric treatment. Partici-
pants will be recruited by clinical psychologists and psy-
chiatrists working in these centers, until the required
sample is complete. In order to facilitate the selection of
participants in the study, both clinical psychologists and
Screening
Randomized
(n = 200) 
Excluded
(n =  ) 
Not meeting elegibility
criteria
(n =  ) 
Refused to participate
(n =  ) 
Other reasons
(n =  ) 
Baseline assessment
EmotionRegulation
(n = 100) 
Post-assessment
3-month follow-up 
TAU 
(n = 100) 
12-month follow-up 
Fig. 1 Study flowchart. EmotionRegulation, transdiagnostic Internet-based protocol; TAU, treatment as usual
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psychiatrists will be given a sheet containing the eligibility
criteria.
Ethics
This trial will be conducted in compliance with the
study protocol, the Declaration of Helsinki and good
clinical practice. Data security/confidentially will be
guaranteed; all relevant EU legislation and international
texts on privacy will be observed and respected. Access
to the Internet platform is through a unique username-
password combination and will be available on a 24/7
basis. All transferred data will be secured via AES-256
encryption.
The study has been approved by the Ethics Committee
of University Jaume I (Castellon, Spain) and the Clinical
Research Ethics Committee from two hospitals (Consorcio
Hospitalario Provincial de Castellon, and Hospital
Universitario de la Ribera). The trial was registered at
clinicalstrials.gov as NCT02345668. For ethical rea-
sons, patients allocated to TAU will be offered free
access to EmotionRegulation after the study has been
completed.
Eligibility criteria
Inclusion criteria will include the following: a) be
18 years or older; b) ability to understand and read
Spanish; c) access to Internet at home and having an
email address; d) meeting the DSM-IV diagnostic criteria
[78] for ED (MDD, DD, MDNOS, PD, A, SAD, GAD,
ADNOS, OCD); and e) providing written, informed con-
sent. Exclusion criteria include the following: a) suffering
from a severe mental disorder (schizophrenia, bipolar
disorder, and alcohol and/or substance dependence dis-
order); b) the presence of a high risk of suicide; c) med-
ical disease/condition that prevents the participant from
carrying out the psychological treatment; or d) receiving
another psychological treatment during the study in the
experimental group. Receiving pharmacological treat-
ment is not an exclusion criterion during the study
period, but patients having an increase and/or change in
the medication 2 months prior to enrollment will not be
considered for the trial. Also, the increase and/or change
in the medication during the study period in the experi-
mental group will imply the participant’s exclusion from
subsequent analyses (a decrease in pharmacological
treatment is accepted).
Recruitment
When the psychiatrist or clinical psychologist identifies
a potential participant, he or she will describe the study
characteristics to him/her. Those candidates interested
in participating will sign an informed consent, and the
professional will fill out a document describing the par-
ticipant’s sociodemographic and clinical characteristics,
and give him/her a patient information sheet and a
handout describing the study. After confirming that the
participant has signed the informed consent and under-
stands the study and the treatment options, the re-
searcher will administer assessment instruments related
to the inclusion criteria. If the patient fulfills all the
study criteria, the researcher will contact an independent
researcher to implement randomization. Participants
who meet all the inclusion criteria will then be random-
ized to either EmotionRegulation or TAU and complete
the remaining assessment instruments. Participants will
be free at any time to withdraw from the treatment or
the study without giving any explanation.
Randomization and blinding
Patients will be randomly allocated in a 1:1 ratio to
either of the two groups (EmotionRegulation or TAU)
using a computer-generated random number sequence.
The Epidat 4.1 program will be used to generate this
sequence. The allocation will be carried out by an inde-
pendent researcher who will be unaware of the charac-
teristics of the study. The sequence will be concealed
until interventions are assigned. Patients will agree to
participate before the random allocation and without
knowing to which treatment they will be allocated. Study
researchers conducting psychological assessments (that
is, diagnostic interviews) throughout the entire study will
be masked to the participants' treatment conditions and
unaware of the treatment group to which the patient
belongs. For ethical and practical reasons, participants
will not be blind to the treatment conditions.
Interventions
Transdiagnostic Internet-based protocol (EmotionRegulation)
Our research group developed a transdiagnostic protocol
made up of 12 modules designed for the treatment of
the following mental disorders: MDD, DD, MDNOS,
PD, A, SAD, GAD, ADNOS and OCD. This protocol is
partly based on the UP by David H. Barlow [37] and
partly on the emotion regulation skills from DBT by
Marsha Linehan [52]. The intervention aims to enhance
present-focused emotional awareness, facilitate cognitive
flexibility, identify and modify behavioral and emotional
avoidance patterns, and promote interoceptive and situ-
ational exposure. Each module includes several tasks to
practice the different techniques and skills.
We have adapted this protocol for its application on
the Internet (EmotionRegulation). EmotionRegulation
is an internet-delivered, multimedia, interactive, self-
administered program for ED that allows the individ-
uals to learn and practice adaptive ways to regulate
their emotions from a transdiagnostic perspective.
EmotionRegulation will be delivered through a web plat-
form (https://www.psicologiaytecnologia.com/) designed
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by our research group. This web platform has four main
sections (shown in Table 1).
EmotionRegulation includes a Welcome module that
provides the participant with general information about
the protocol and its objectives, as well as recommenda-
tions for benefiting from it, and the following 12 treat-
ment modules:
M1. Emotional disorders and emotion regulation. This
module provides information about the role of emotion
regulation in emotional disorders. A brief description
of the program modules is also presented, as well as
videos with examples of people suffering from different
ED.
M2. Motivation for change. The aims are to analyze the
advantages and disadvantages of changing, emphasize
the importance of being motivated, and highlight the
importance of establishing significant life goals.
M3. Understanding the role of emotions. This module
provides information about the adaptive roles and
functions of emotions and the three-component model
of emotions.
M4. The acceptance of emotional experiences. This
module aims to teach the patient the acceptance of
emotional experiences and its importance in the
treatment.
M5. Practicing acceptance. The objective is to continue
to learn about the acceptance of emotional experiences
and increase awareness of physical sensations, thoughts,
emotions and daily activities.
M6. Learning to be flexible. It focuses on the importance
of maladaptive ways of thinking in the maintenance of
emotional disorders, and on learning how to identify
them.
M7. Practicing cognitive flexibility. This module aims
to teach the patients the ways maladaptive ways of
thinking can be modified. It also provides information
about intrusive thoughts and how to deal with them.
M8. Emotional avoidance. This module aims to teach
the patients the emotion avoidance strategies that
contribute to the maintenance of emotional disorders.
M9. Emotion Driven Behaviors (EDBs). The aim is to
learn the concept of EDBs, and replace their own
maladaptive EDBs with other more adaptive behaviors.
M10. Accepting and facing physical sensations. The
objectives are to teach the patients the role of physical
sensations in the emotional response and train them in
interoceptive exposure, in order to increase tolerance
and promote habituation to physical sensations.
M11. Facing emotions in the contexts in which they
occur. The purpose is the construction of exposure
hierarchies to help the patients to begin to face the
avoided situations that contribute to the maintenance
of the problem.
M12. Relapse prevention. This module aims to review
the strategies learned throughout the program and
teach the patient how to identify and cope with future
high-risk situations.
These modules are sequential, in order to move
through the program step by step. The program dur-
ation can vary among the users, and it is estimated that
for most participants the duration will be 18 weeks. Dur-
ing the study, EmotionRegulation will be accessible only
to participants in the online intervention group. Partici-
pants will be allowed to use the program at any time
they want during the trial period. See Table 2 for other
functionalities in EmotionRegulation.
Participants in the EmotionRegulation condition will
be allowed to maintain medication if there are not
changes and/or increases but will not be allowed to
receive another psychological treatment during the
study period. Failure to fulfill these criteria will result
in the participant’s data being excluded from data
analysis.
Table 1 Main sections of the web platform
(https://www.psicologiaytecnologia.com/)
a) “Home”: This section is the start point from which participants can
access the other sections. It also displays a progress bar (0 to 100 %)
that shows the progress through the treatment.
b) “Calendar”: This section shows pending tasks as well as the days in
which the participant has accessed the program and has done the
module tasks.
c) “Review”: This section allows participants to review the treatment
modules already done as many times as they want.
d) “How am I?”: This section allows participants to monitor their
progress through several graphs as they advance in the program.
Table 2 Other functionalities in EmotionRegulation
a) Assessments: The program allows the pre-, post- and follow-up
instruments to be completed online.
b) Module self-assessments: Each module ends with a short list of
multiple-choice questions that allow participants to assess their
understanding of the module and help them to decide whether they
need to review its contents.
c) Automatic e-mails with reminders when participants have not
accessed the program in the past 15 days.
d) Suicide risk alarms: Therapists receive warnings of participants with
high risk of suicide (when participants answer questionnaires that
include items assessing high suicide risk)
e) Post-module questionnaires: Each module includes three brief
questionnaires (OASIS, ODSIS and PANAS) to evaluate anxiety,
depression and positive/negative affect after each treatment module.
Participants are able to monitor these scores in the feedback section
through the ‘How am I?’ button.
f) Printable documents: Each module contains several printable
documents (PDF) with summaries and self-monitoring sheets that
participants are encouraged to use to practice the skills and strategies.
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Treatment as usual
Treatment as usual (TAU) is treatment as delivered in
current daily practice by psychiatrists and clinical psy-
chologists in the mental health centers in Spain. TAU
may refer to psychiatric treatment, which typically in-
cludes prescription and monitoring of antidepressant
and/or anxiolytic medication, psychological treatment
(this may include case management, group psychother-
apy, empathic listening and/or supportive counselling),
or a combination of both. Patients in the TAU condition
already receiving any of the aforementioned treatments
are informed they will continue to receive as usual the
services received before enrollment in the study.
Support
Meta-analyses have shown that attrition rates are higher
when no support of any kind is provided to patients in
self-administered Internet-based programs [60, 68].
Therefore, we will provide human support and ICT
support to all participants in EmotionRegulation.
Human support will be provided by trained pre-
doctoral students in our group and will include the fol-
lowing: a) an initial face-to-face session to explain the
participant the characteristics of the study and to admin-
ister the diagnostic interview to confirm him/her to
fulfill the eligibility criteria, b) an initial phone call en-
couraging participants to start the intervention once
baseline assessments have been completed, and c) one
weekly brief phone call (maximum of 10 minutes) dur-
ing the treatment period. The objective of these weekly
phone calls will be as follows: 1) to ask the participants
about any difficulties or doubts they might have found
in the use of the online protocol and help them to solve
those problems, 2) to remind them to review the treat-
ment contents as many times as necessary, 3) to
emphasize the importance of doing the homework tasks,
4) to encourage participants to keep using the protocol
and reinforce them for engaging in the treatment,
and 5) to recommend that they complete one module
per week. Finally, d) a final phone call will be made
after the 18-week treatment period to remind partici-
pants that they will be allowed to use the program at
any time they want during the trial period and that
they will be contacted for follow-up assessments.
ICT support will consist of two weekly mobile phone
text messages with reminders about the importance
of doing the homework tasks and encouraging partici-
pants to review the modules. A commercial platform
(www.trendoo.es) will be used to send these messages.
Instruments
Patients will be assessed at baseline, post-treatment
(18 weeks after baseline), and at 3- and 12-month
follow-ups. Scores on anxiety, depression and negative
and positive affect will also be obtained after each mod-
ule has been completed. The study variables and assess-
ment times are summarized in Table 3.
Diagnosis interview
Mini International Neuropsychiatric Interview Version
5.0.0 (MINI) [79]. It is a short structured diagnostic psy-
chiatric interview that yields key DSM-IV and ICD-10
diagnoses. The MINI can be administered in a short
period of time, and clinical interviewers need only brief
training. The MINI has been translated into Spanish and
validated [80].
Primary outcomes
Beck Anxiety Inventory (BAI) [81]. The BAI is a 21-item
self-report measure designed to assess anxiety, with a
maximum of 63 points. Each item has a four-point
Table 3 Study variables and assessment points
Instrument Assessment area Time of assessment
MINI Neuropsychiatric Psychiatric diagnosis Baseline, Post-T
and follow-ups
Interview
BAI Severity of anxiety Baseline, Post-T
and follow-ups
BDI-II Severity of depression Baseline, Post-T
and follow-ups
Sociodemographic
data
Gender, age, marital status,
education, occupation,
economic level
Baseline
OASIS Severity of anxiety Post-module
ODSIS Severity of depression Post-module
SIAS Severity of SAD symptoms Baseline, Post-T
and follow-ups
PDSS-SR Severity of PD and
agoraphobia symptoms
Baseline, Post-T
and follow-ups
PSWQ Severity of GAD symptoms Baseline, Post-T
and follow-ups
OCI-R Severity of OCD symptoms Baseline, Post-T
and follow-ups
EQ-5D Health-related quality of life Baseline, Post-T
and follow-ups
PANAS Positive and negative affect Post-module
BIS-BAS Behavioral inhibition/activation Baseline, Post-T
and follow-ups
ETS Expectation of treatment Baseline
OTS Opinion of treatment Post-T
Post-T, post-treatment (18 weeks after baseline); follow-ups, 3- and 12-month
follow-ups. BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II;
OASIS, Overall Anxiety Severity and Impairment Scale; ODSIS, Overall
Depression Severity and Impairment Scale; SIAS, Social Interaction Anxiety
Scale; PDSS-SR, Self-Reported Panic Disorder Severity Scale; PSWQ, Penn
State Worry Questionnaire; OCI-R, Obsessive-Compulsive Inventory-Revised;
EQ-5D, EuroQoL-5D questionnaire PANAS, Positive and Negative Affect
Scale; BIS-BAS, Behavioral Inhibition and Behavioral Activation Scales; ETS,
Expectation of Treatment Scale; OTS, Opinion of Treatment Scale
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severity scale (for example, not at all, mildly, moderately,
and severely) that addresses symptoms experienced dur-
ing the past week. The internal consistency of the BAI
has been found to range from .85 to .94, and it has
shown adequate convergent and divergent validity. The
Spanish version of the BAI has shown high internal
consistency (α = .93) [82].
Beck Depression Inventory (BDI-II) [83]. It is one of
the most widely used questionnaires to evaluate depres-
sion severity in pharmacological and psychotherapy tri-
als. It consists of 21 items about the different symptoms
characterizing major depression disorder, added together
to obtain the total score, which can be a maximum
of 63 points. The instrument has good internal
consistency (α = 0.76 to 0.95). The Spanish version of
this instrument has also shown a high internal
consistency (α = 0.87) for both the general and clinical
populations (α = .89) [84].
Secondary outcomes
Sociodemographic variables The following sociodemo-
graphic variables will be collected: gender, age, marital
status (single, married/relationship, separated/divorced,
and widowed), education (years of education), and work
status.
Diagnosis-specific measures In order to evaluate the
specific anxiety disorder shown by each participant, four
different instruments will be implemented. One of the
four following questionnaires will be selected and in-
cluded at pre, post-treatment, and 3- and 12-month
follow-up assessments, depending on the main diagnosis
given to each participant.
SAD: Social Interaction Anxiety Scale (SIAS) [85]. This
scale is made up of twenty items rated from 0 to 4 that
assess the anxiety experienced by the patient in social
interaction situations. The scale has good internal
consistency (α = .88 to .94), good test-retest and discrim-
inant reliability, and appropriate construct validity. The
Spanish validation showed adequate internal consistency
and good construct validity [86].
PD/A: Self-Reported Panic Disorder Severity Scale
(PDSS-SR) [87]. The scale evaluates the severity of the
PD symptomatology through measures of panic attack
frequency, distress during panic attacks, anticipatory
anxiety, fear and agoraphobic avoidance, fear and avoid-
ance of physical sensations, and work and social impair-
ment. Scale reliability (α = .917) and test-retest reliability
(ICC = .81) were shown to be excellent. The psychomet-
ric analysis of the Spanish version showed excellent
internal consistency (α = .85), good test-retest reliability,
and adequate convergent validity [88].
GAD: Penn State Worry Questionnaire (PSWQ) [89],
which evaluates worry as an uncontrollable, generalized
and excessive experience. The PSWQ has good psycho-
metric properties, with an internal consistency ranging
from .91 to .95, and good validity and test-retest reliability.
The Spanish version of the scale showed an internal
consistency of .90 and a test-retest reliability of .82, as well
as adequate convergent and discriminant validity [90].
OCD: Obsessive-Compulsive Inventory-Revised (OCI-R)
[91]. The OCI-R is a scale made up of 18 items rated from
1 to 4 and organized in six dimensions (washing, verifica-
tion, order, obsession, hoarding and mental neutralization)
that assess obsessive-compulsive behaviors. The OCI-R has
showed good internal consistency (α = .81 to .93), good to
excellent test-retest reliability (α = .57 to .91) and
good convergent validity. The internal consistency of
the Spanish version of the OCI-R has been found to
be good (α = .86) [92].
N/BI and E/BA Behavioral Inhibition and Behavioral
Activation Scales (BIS/BAS) [93]. These scales were de-
signed to assess two temperaments identified in Gray’s
biobehavioral theory of emotion [94], namely, behavioral
inhibition and behavioral activation. The scale is made
up of 20 items rated from 1 to 4, with seven BIS subscale
items that evaluate individuals’ emotional responses to
impending negative events and 13 BAS items that assess
individuals’ behavioral and emotional responses to po-
tentially positive events. The BIS/BAS have demon-
strated good reliability in a large sample of individuals
with emotional disorders (α = .73 to .92), and stronger
associations with other measures of temperament (that
is, neuroticism/negative affect and extraversion/positive
affect, respectively) than with measures of anxiety or de-
pressive disorder constructs, suggesting that they have
good convergent and discriminant validity as indicators
of temperament [95]. The internal consistency of the
Spanish version ranges between .65 and .82 [96].
Post-module measures Overall Anxiety Severity and
Impairment Scale (OASIS) [97]. The OASIS consists of
a 5-item questionnaire, rated from 0 to 4, that assesses
the frequency and severity of the anxiety symptoms. The
instrument also provides measures of avoidance, as well
as work, academic, social and everyday life impairment
related to anxiety symptoms. A psychometric analysis
of the OASIS scale found good internal consistency
(α = .80), test-retest reliability (k = .82) and convergent
validity for this instrument.
Overall Depression Severity and Impairment Scale
(ODSIS) [98]. The ODSIS is a self-report measure with
five items that evaluate experiences related to depres-
sion. The ODSIS measures the frequency and severity of
depression, as well as the level of avoidance, work/
school/home interference, and social interference associ-
ated with depression. The internal consistency of the
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scale has been shown to be excellent, with a Cronbach's
alpha between .91 and .94 and good convergent and dis-
criminant validity. The Spanish psychometric properties
of both the OASIS and the ODSIS are being studied by
members of our research team at the time of the publi-
cation of this paper.
Positive and Negative Affect Scale (PANAS) [99]. The
PANAS consists of 20 items that evaluate two independ-
ent dimensions: positive affect (PA) and negative affect
(NA). The range for each scale (10 items on each) is
from 10 to 50. The Spanish version has demonstrated
high internal consistency (α = 0.89 and 0.91 for PA
and NA in women, respectively, and α = 0.87 and 0.89
for PA and NA in men, respectively) in college stu-
dents [100].
Quality of life EuroQoL-5D questionnaire (EQ-5D)
[101]. It is a generic instrument that measures health-
related quality of life and consists of two parts: Part 1 as-
sesses self-reported problems in each of five domains:
mobility, self-care, daily activities, pain/discomfort and
anxiety/depression. Each domain is divided into three
levels of severity corresponding to no problems, some
problems, and extreme problems, yielding a population-
based preference score or societal index (SI). A total of
243 theoretically possible health states can be obtained,
and the SI is calculated on the basis of these health
states. Values range from 1 (best health state) to 0
(death). However, this index may also provide negative
values that correspond to health states perceived as
worse than death. Utility scores for these health states
were assigned using readily available Spanish population
tariffs [102]. Part 2 records the subject's self-assessed
health on a visual analogical scale (VAS), a 10 cm verti-
cal line on which the best and worst imaginable health
states score 100 and 0, respectively.
Treatment expectations and treatment opinion Ex-
pectation of Treatment Scale (ETS) and Opinion of
Treatment Scale (OTS). These questionnaires are
adapted from Borkovec and Nau [103]. The content of
the six items, rated on a scale from 0 to 10, cover how
logical the treatment seemed, to what extent it could sat-
isfy the patient, whether it could be used to treat other
psychological problems, its usefulness for the patient’s
specific problem, and to what extent the treatment could
be aversive. The expectation scale is applied once the
treatment rationale has been explained, at the end of the
welcome module. Its aim is to measure subjective pa-
tient expectations about this treatment. The opinion
scale is administered when the patient has completed
the treatment, and its aim is to assess satisfaction with
this treatment. Our group has used this questionnaire in
several research studies [104, 105].
Sample size
The data from an RCT using the UP yielded between-
group effect sizes of 0.56 for anxiety and 1.11 for depres-
sion, as measured with the BAI and BDI-II, respectively
[30]. As we aim to compare the intervention with a TAU
group, the results of a meta-analysis comparing CBT trans-
diagnostic treatments versus TAU have also been consid-
ered in the estimation of the expected sample size [106].
This meta-analysis reported a medium post-treatment ef-
fect size of 0.44 for depression and of 0.34 for anxiety
between transdiagnostic treatment protocols vs. TAU con-
ditions. The type of support we provide in this intervention
(contact with researchers before, during and after the treat-
ment period) has also been taking into account when esti-
mating the expected sample size, as defined in a previous
meta-analysis focused on Internet-based psychological
treatments for depression [107]. Based on a power of .80 in
a one-tailed test, an alpha of .05, and an estimated drop-out
rate of around 30 % [65, 108] we need a sample size of 100
per condition to detect a post-treatment effect size of 0.40
(Cohen’s d) between both groups. Therefore, the total
sample size was determined at 200.
Analysis
Intention-to-treat analyses and per protocol analyses will
be performed. Reporting of the results will follow CON-
SORT recommendations [75, 76]. First, the two groups
will be compared in order to verify that there are no
significant differences between them at baseline using
samples t-tests for continuous distributed variables and
chi-squares test of independence for categorical to con-
firm that they are comparable after randomization.
The intention-to-treat principle will be used when ana-
lyzing primary and secondary post-treatment data and
data collected at the 3- and 12-month follow-ups using
mixed effect models with full information maximum like-
lihood estimation. This method has been recommended
for its flexibility over repeated-measures ANOVAs to han-
dle missing date more appropriately [109].
Within and between-group changes will be computed
calculating standardized effect sizes (Cohen’s d). Cohen’s d
is calculated by dividing the differences between means by
the pooled standard deviation [110]. An effect size of 0.20
is considered to be small, of 0.50 to be moderate, and 0.80
and above to be large [110].
Per protocol analyses (compliers only analysis) will
also be conducted. Despite this procedure suffers from
selection bias, it can help to draw conclusions about the
maximum treatment efficacy in patients who comply
fully with the treatment [111].
As the trial is still in execution, the state of the art re-
garding analytic methodology for RCT will be reviewed
before analyzing the data, thus variations in the selection
of the most appropriate analytic procedures may occur.
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Discussion
This study has several aims. The first is to provide data
from a RCT about the effectiveness of a transdiagnostic
Internet-based protocol for the treatment of ED in a
sample of participants from specialized care in the
Spanish public mental health system, compared to TAU.
Second, whether the treatment may temper the psycho-
logical vulnerability by analyzing its effect on psycho-
logical higher-order dimensions (neuroticism/behavioral
inhibition and positive affect/behavioral activation) will
be studied. The third aim is to study the acceptability of
this online program by patients in an ecological setting
(public specialized care in Spain).
The advantages of a transdiagnostic Internet-based
protocol are two-fold. First, a wide range of ED can be
treated with a single protocol, reducing the costs associ-
ated with disorder-specific protocols and contributing to
solving the problem of comorbidity and NOS diagnoses,
as the protocol focuses more on the common patho-
logical processes than on any specific disorder and/or
symptomatology. Second, Internet-based protocols can
help to disseminate CBT evidence-based treatments, so
that more people can benefit from them. This study will
provide additional data about the transdiagnostic per-
spective proposed by Barlow [20], as well as data on the
combination of a transdiagnostic perspective and the use
of ICTs.
In addition, this study has various strengths. First, this
is the first RCT of transdiagnostic Internet-based psy-
chotherapy in specialized care in our country. Positive
results achieved with this protocol may have an import-
ant impact, since protocols of this type could help to de-
crease the saturation of the public mental health system,
reducing costs and contributing to a general improve-
ment in the public mental health services in our country
(for example, reductions in waiting lists, hours of clinical
assistance and hours of face-to-face treatment; a higher
number of patients who receive psychological treatment;
etcetera). Second, the online protocol combines the
transdiagnostic cognitive-behavioral principles (psycho-
education about emotions, enhancement of cognitive
flexibility, interoceptive and situation-based emotion ex-
posure) with components of acceptance and emotion
regulation for the treatment of ED. The data obtained
with this protocol can help us to understand the psycho-
pathology of these mental disorders. And third, even
though transdiagnostic Internet-based protocols are
thought to treat different ED, most of the existing
studies exclusively target anxiety disorders [25, 26, 73],
and others have used open-trial designs [28, 74] and do
not contemplate either the diagnosis of obsessive-
compulsive disorder or NOS diagnoses [29] or they
focus on a smaller number of ED [29]. We consider that
this study broadens the current literature about
transdiagnostic Internet-based protocols as it is designed
for a wide range of anxiety and depressive disorders.
Combining the advantages of both a more inclusive
transdiagnostic intervention and an Internet-based deliv-
ery format may broaden the scope of evidence-based
treatments among the population in need. Moreover, the
population in which the study is being conducted, that
is, patients who attend a variety of public specialized
care settings across Spain, can help to draw conclusions
about the external validity of the intervention.
Finally, a number of potential limitations should be in-
dicated. First, dropout rates are expected to be high
(around 30 %) [67, 110]. Efforts to maintain these drop-
out rates below this percentage will be made by provid-
ing human support (before, during, and after the inter-
vention) and ICT-support (for example, emails and
mobile phone text messages). Second, negative attitudes
towards Internet interventions by both clinicians and pa-
tients may affect recruitment as well as dropout rates.
To minimize the effect of negative attitudes, the nature
and characteristics of the intervention will be explained
to clinicians involved in the trial. Moreover, for this pur-
pose they will be given a handbook with relevant infor-
mation about the study (for example objectives of the
study, study design, and characteristics of the interven-
tion). In order to increase participant’s credibility, prior
to enrollment they will be given a sheet with relevant in-
formation concerning the characteristics and objectives
of the study, and other issues related to ethics, voluntary
participation and confidentiality of the data. Finally,
other difficulties could be problems with recruitment, as
many people who attend public mental health units do
not have access to the Internet at home.
Trial status
The trial is active and recruiting.
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